.Pharmacolibrary.Drugs.ATC.L.L01EM04 .Pharmacolibrary.Drugs.ATC.L.L01EM04| name: | Duvelisib |
| ATC code: | L01EM04 | route: | oral |
| n-compartments | 1 |
Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase delta and gamma (PI3K-δ and PI3K-γ) isoforms. It is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma after at least two prior therapies.
Pharmacokinetic parameters reported following oral administration of duvelisib (25 mg twice daily) in adult cancer patients, including CLL/SLL.